Spero Therapeuti Financials

Spero Therapeuti (SPRO) reported $48.0M in total revenue for fiscal year 2024. This represents a -53.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Spero Therapeuti (SPRO) revenue declined by 53.8% year-over-year, from $103.8M to $48.0M in fiscal year 2024.

No, Spero Therapeuti (SPRO) reported a net income of -$68.6M in fiscal year 2024, with a net profit margin of -142.9%.

Spero Therapeuti (SPRO) reported diluted earnings per share of $-1.27 for fiscal year 2024. This represents a -395.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Spero Therapeuti (SPRO) had EBITDA of -$73.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Spero Therapeuti (SPRO) had an operating margin of -152.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

Spero Therapeuti (SPRO) had a net profit margin of -142.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Spero Therapeuti (SPRO) generated -$23.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Spero Therapeuti (SPRO) had $110.5M in total assets as of fiscal year 2024, including both current and long-term assets.

Spero Therapeuti (SPRO) invested $96.8M in research and development during fiscal year 2024.

Spero Therapeuti (SPRO) had 55M shares outstanding as of fiscal year 2024.

Spero Therapeuti (SPRO) had a current ratio of 2.19 as of fiscal year 2024, which is generally considered healthy.

Spero Therapeuti (SPRO) had a debt-to-equity ratio of 1.40 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Spero Therapeuti (SPRO) had a return on assets of -62.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Spero Therapeuti (SPRO) had $52.9M in cash against an annual operating cash burn of $23.4M. This gives an estimated cash runway of approximately 27 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Spero Therapeuti (SPRO) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Spero Therapeuti (SPRO) has an earnings quality ratio of 0.34x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Spero Therapeuti (SPRO) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.